Bcal Diagnostics Limited
BDX.ASXHealth Care
BCAL Diagnostics Limited is a biotechnology company developing a blood based diagnostic test for breast cancer.
Market Data
$0.080
+0.0%$28.2M
-100000.0x
$-0.020
0.00%
-0.2%
Recent Announcements
BCAL Half Year Results Presentation December 2025
BCAL reported improved H1 FY26 results with revenue of $1.3M (down 8.1% from prior period) but reduced net loss to $3.9M from $4.0M. The company successfully launched new Avantect pancreatic and ovarian cancer tests, sold 215 BREASTESTplus tests, and strengthened its balance sheet with $10M convertible note facility and $3.3M cash on hand. Key points: Successfully launched Avantect pancreatic and ovarian cancer tests with strong early demand (1,000 enquiries, 60 bookings, 30 tests in first 10 days); Sold 215 BREASTESTplus tests and expanded to 20 clinics supported by 90 doctors across NSW; Strengthened balance sheet with $10M convertible note facility and received $2.5M R&D tax incentive
BCAL Webinar Review Half Year Results 18 February 11am AEDT
This is a webinar announcement for BCAL Diagnostics' 1H FY26 results presentation scheduled for February 18, 2026, not actual earnings results. No financial metrics or performance data are disclosed in this announcement. Key points: Company will present 1H FY26 results with Executive Chair and CEO participation; Q&A session will be available for investor engagement; Maintains exclusive licensing agreement with ClearNote Health for cancer detection tests
Get real-time alerts for BDX
Receive AI-powered earnings summaries and instant notifications when Bcal Diagnostics Limited releases results.
Register Free